文献类型：期刊文献

英文题名：Type I insulin-like growth factor receptor signaling in hematological malignancies

作者：Vishwamitra, Deeksha[1];George, Suraj Konnath[1];Shi, Ping[2];Kaseb, Ahmed O.[3];Amin, Hesham M.[1,4]

机构：[1]Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA;[2]East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai, Peoples R China;[3]Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA;[4]Univ Texas Grad Sch Biomed Sci, Houston, TX USA

年份：2017

卷号：8

期号：1

起止页码：1814

外文期刊名：ONCOTARGET

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000391503300142)】；

基金：This work is supported by an R01CA151533 grant from the National Cancer Institute (NCI) to H.M.A., an R21CA170035 grant from the NCI to A.O.K., and by grant 14520720700 from Shanghai Scientific and Technological Innovation Project to P.S. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NCI or the National Institutes of Health.

语种：英文

外文关键词：IGF-IR; plasma cell myeloma; leukemia; lymphoma

摘要：The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that the type I IGF receptor (IGF-IR) and its primary ligand IGF-I are important for maintaining the survival of malignant cells of hematopoietic origin. In this review, we discuss current understanding of the role of IGF-IR signaling in cancer with a focus on the hematological neoplasms. We also address the emergence of IGF-IR as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma.